NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDBendamustine  Malignant disease and immunosuppression, Alkylating drugs, 08.01.01
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Bendamustine Bendamustine Hydrochloride [Specialist Drug] Malignant Disease, Cytotoxic Responsive Malignancy, Antineoplastic Drugs Alkylating Agents
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
DSU July 2017: Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation
NICE TA 649 Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
NICE TA216: Bendamustine for CLL
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma